<DOC>
	<DOCNO>NCT00000996</DOCNO>
	<brief_summary>To study natural course AIDS relate Kaposi 's sarcoma determine usefulness safety weekly administration small dos doxorubicin . Doxorubicin one active antitumor agent currently use dos toxicity common . When small dos administer weekly schedule , toxicity drug appear reduce .</brief_summary>
	<brief_title>A Study Doxorubicin Treatment AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>Doxorubicin one active antitumor agent currently use dos toxicity common . When small dos administer weekly schedule , toxicity drug appear reduce . Patients stratify non-therapy purpose 2 group ; doxorubicin give intravenously ( IV ) every week outpatient basis . Patients monitor carefully , weekly blood sample take determine effectiveness safety treatment . Patients evaluate toxicity one dose drug weekly thereafter . Patients evaluated response drug 4 week monthly thereafter .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Ongoing and/or maintenance therapy opportunistic infection . Medications nausea , vomit , diarrhea result drug . Patients must AIDS relate Kaposi 's sarcoma . Patients may demonstrate positive blood culture Mycobacterium aviumcomplex cytomegalovirus . Exclusion Criteria Coexisting Condition : Patients follow condition exclude : Patients active opportunistic infection . Patients concurrent neoplasm squamous cell carcinoma skin situ carcinoma cervix . Patients significant neurologic , cardiac , liver disease . Concurrent Medication : Excluded : Antiretroviral agent . Immunomodulators . Corticosteroids . Experimental drug . The following patient exclude study : Patients lymphadenopathy alone and/or visceral disease alone secondary Kaposi 's sarcoma . Prior Medication : Excluded : Cytotoxic chemotherapy . Excluded within 30 day study entry : Antiretroviral agent . Biologic modifier . Corticosteroids . Prior Treatment : Excluded : Total body electron beam therapy . Excluded within 30 day study entry : Radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Doxorubicin</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>